Canopy Growth (CGC) Total Non-Current Liabilities (2017 - 2026)

Canopy Growth (CGC) reported Total Non-Current Liabilities of $279.8 million for Q1 2026, little changed on a YoY basis from $280.8 million in Q1 2025, and up 12.13% sequentially from $249.6 million in Q4 2025.

Canopy Growth (CGC) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends

Canopy Growth (CGC) has 10 years of Total Non-Current Liabilities data on file, last reported at $279.8 million in Q1 2026.

  • For the quarter ending Q1 2026, Total Non-Current Liabilities changed 0.33% year-over-year to $279.8 million; the trailing twelve-month figure through Mar 2026 stood at $279.8 million (changed 0.33% YoY), and the FY2026 full-year result was $279.8 million, changed 0.33% from the prior year.
  • Total Non-Current Liabilities climbed to $279.8 million in Q1 2026, from $249.6 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $1.5 billion in Q1 2022 to a low of $242.6 million in Q3 2025.
  • A 5-year average of $726.7 million and a median of $598.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
  • Across the five-year window, Total Non-Current Liabilities tumbled 54.31% in 2025 and fell 0.33% in 2026, its largest moves.
  • Tracing CGC's Total Non-Current Liabilities over 5 years: stood at $1.1 billion in 2022, then plunged by 47.26% to $598.7 million in 2023, then slumped by 31.52% to $410.0 million in 2024, then sank by 39.13% to $249.6 million in 2025, then advanced by 12.13% to $279.8 million in 2026.
  • Business Quant data shows CGC's Total Non-Current Liabilities at $279.8 million in Q1 2026, $249.6 million in Q4 2025, and $242.6 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Non-Current Liabilities (Qtr)
1 Haleon 87.22 Bn 85.35 Bn - 14.92 Bn
2 Teva Pharmaceutical Industries 39.60 Bn 35.87 Bn 1.97 Bn 18.28 Bn
3 Zoetis 31.46 Bn 29.52 Bn 1.62 Bn 11.64 Bn
4 Takeda Pharmaceutical 26.49 Bn 22.44 Bn 4.39 Bn 33.47 Bn
5 United Therapeutics 23.03 Bn 20.88 Bn 648.10 Mn 599.10 Mn
6 Universe Pharmaceuticals 23.03 Bn -10.56 Bn - -
7 Viatris 20.90 Bn 19.09 Bn 1.16 Bn 20.09 Bn
8 Neurocrine Biosciences 17.50 Bn 16.19 Bn 800.70 Mn 1.24 Bn
9 Elanco Animal Health 12.33 Bn 11.91 Bn 785.00 Mn 6.26 Bn
10 Canopy Growth 197.77 Mn -68.15 Mn - 279.84 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 279.84 Mn
Dec 31, 2025 249.56 Mn
Sep 30, 2025 242.57 Mn
Jun 30, 2025 300.01 Mn
Mar 31, 2025 280.76 Mn
Dec 31, 2024 410.00 Mn
Sep 30, 2024 529.76 Mn
Jun 30, 2024 550.77 Mn
Mar 31, 2024 614.43 Mn
Dec 31, 2023 598.71 Mn
Sep 30, 2023 685.33 Mn
Jun 30, 2023 926.46 Mn
Mar 31, 2023 1.24 Bn
Dec 31, 2022 1.14 Bn
Sep 30, 2022 1.34 Bn
Jun 30, 2022 1.42 Bn
Mar 31, 2022 1.55 Bn
Dec 31, 2021 1.51 Bn
Sep 30, 2021 1.64 Bn
Jun 30, 2021 2.10 Bn